Sourcing Exosomes in Wyoming
Licensed Wyoming practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Wyoming buyers need their own professional license and NPI; the wholesale distributor license is the supplier’s obligation, not the purchaser’s.
Wyoming enacted the Stem Cell Freedom Act in 2026, the most physician-permissive stem cell statute in the country, passed without a single no vote. Its reach is narrower than its name: the Act is written around the patient’s own mesenchymal stem cells, administered by a physician registered with the Board of Medicine. It is worth knowing exactly what that statute covers, and what it does not.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Wyoming? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | SF 48 (Enrolled Act 31) (2026) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Wyoming
ExaVeyra ships to licensed practices in all 50 states, Wyoming included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Wyoming professional license in good standing, verifiable through the Wyoming Board of Medicine or the Wyoming State Board of Nursing.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Wyoming sales tax license and resale documentation through the Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Wyoming licenses every entity engaged in the distribution of prescription drugs into or from the state through the State Board of Pharmacy, under Wyo. Stat. 33-24-153 and chapter 8 of the Pharmacy Act rules. The Board maintains three types of wholesale distributor license for different business activities, states expressly that virtual entities are not exempt, and renews the licenses annually on 30 June. The license sits with the distributor, not with the purchasing practice.
Wyo. Stat. § 33-24-153; Wyoming Pharmacy Act Rules ch. 8 · Wyoming State Board of Pharmacy
Wyoming regenerative-medicine law
Wyoming enacted SF 48 (Enrolled Act 31), codified at Wyo. Stat. §§ 35-4-1101 to 35-4-1106, effective 1 July 2026.
Physicians licensed by the Wyoming Board of Medicine under title 33, chapter 26; the Act’s definition of physician expressly excludes physician assistants. A patient may receive, and a physician may perform, stem cell therapy not approved by the FDA when the Act’s conditions are met: IRB approval or investigational product status, cGMP manufacturing and handling, a physician-patient relationship, Board registration, and written informed consent acknowledging the therapy is not FDA approved and setting out risks and the patient’s financial responsibility. The Board of Medicine may not act against a registered physician’s license solely for recommending or performing compliant therapy, state officials may not block patient access, and insurers may cover it but are not required to. A person who does not comply with the Act may not perform or advertise therapy under it.
- Autologous mesenchymal stem cells only, the patient’s own
- Institutional review board oversight or investigational product status
- Current good manufacturing practice standards for manufacturing and handling
- Physician registration with the Board of Medicine, which publishes a public registry
- Written informed consent acknowledging the therapy is not FDA approved
- Administration by a physician or under direct physician supervision
“"Stem cell therapy" means treatment involving the use of autologous mesenchymal stem cells, including but not limited to the collection, processing, cultural expansion, manufacturing, storage and therapeutic use of stem cells. "Stem cell therapy" shall not include, whether directly or indirectly, the use of any biological material derived from an abortion”
How this applies to exosomes
The Stem Cell Freedom Act reaches less far than its name suggests, and the limit is in its first definition: stem cell therapy means treatment involving the use of autologous mesenchymal stem cells, the patient’s own, collected, expanded, and returned under physician care. An exosome preparation derived from donor perinatal tissue sits outside that definition twice over: exosomes are acellular extracellular vesicles rather than stem cells, and a donor-derived product is not autologous. The Act therefore neither authorizes nor restricts exosome products, and a state authorization statute is in any case not an FDA approval. Exosome products in Wyoming are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Wyoming practice
Wyoming runs on two models. An APRN-led practice operates on the nurse practitioner’s own authority, with no collaborative filing of the West Virginia or Georgia kind. A physician-led practice delegates conventionally under the Board of Medicine’s oversight. The 2026 Act adds a third, narrow lane on top: a physician who wants to provide autologous stem cell therapy under the Stem Cell Freedom Act registers with the Board of Medicine and appears on its public registry, a registration that has no bearing on ordinary aesthetic or wellness services.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Wyoming Board of Medicine under title 33, chapter 26 perform medical acts within their scope and are the source of delegation in a physician-led practice. Under the Stem Cell Freedom Act, qualifying therapy is administered by a physician or under direct physician supervision, with every other activity physician-supervised as well. |
| NP / APRN | Wyoming advanced practice registered nurses are licensed by the Wyoming State Board of Nursing with full practice authority: they assess, diagnose, prescribe, and provide care in all settings, and the Board states that supervision or collaboration agreements with any other provider are not required by Wyoming law. An APRN-led practice evaluates and orders within its own scope. |
| PA | Physician assistants practice in collaboration with physicians under the Board of Medicine’s framework in title 33, chapter 26. The Stem Cell Freedom Act expressly excludes physician assistants from its definition of physician, so qualifying stem cell therapy under that Act is not a PA service. |
| RN | Registered nurses practice under the Wyoming Nurse Practice Act and the State Board of Nursing’s rules, carrying out treatments on the order of a provider with authority to issue one. An RN does not evaluate the patient independently or set the treatment plan. |
Good faith examination
Wyoming expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Because nurse practitioners hold full practice authority, that provider can be the NP in an NP-led practice. The expectations sit in board standards rather than a named good faith examination statute, so confirm current requirements with the Board of Medicine and the State Board of Nursing.
Ownership and clinic licensing
Wyoming does not codify a corporate practice of medicine prohibition in the way Texas, New York, or Oregon now do. Professional entities with licensed ownership are the conventional structure for a practice, and management services arrangements are common, but because the position is not set out as a bright-line statutory rule, published summaries disagree with one another. The honest answer is that ownership structure in Wyoming is a question for Wyoming counsel and the Board of Medicine rather than one a guide should answer with a percentage. Note one entity-adjacent rule the 2026 Act added: a practice may not advertise stem cell therapy under the Stem Cell Freedom Act unless it complies with the Act, including physician registration.
Cold chain into Wyoming
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Wyoming order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Cheyenne | Laramie | Capital and largest market, on the Front Range lane shared with Colorado. |
| Casper | Natrona | Central Wyoming’s regional medical hub. |
| Jackson | Teton | Resort market with concentrated wellness, longevity, and recovery practices. |
| Cody | Park | Northwestern market serving the Bighorn Basin. |
| Sheridan | Sheridan | North central market near the Montana border. |
| Laramie | Albany | University market southwest of Cheyenne. |
- Wyoming orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Practice types we supply in Wyoming
Wyoming licensing and verification
Wyoming Board of Medicine
Licenses physicians and PAs and keeps the Stem Cell Freedom Act physician registry.
Wyoming State Board of Nursing
Licenses APRNs, who hold full practice authority in Wyoming.
Wyoming State Board of Pharmacy
Licenses the wholesale distributors that ship prescription drugs into Wyoming.
Wyoming Department of Revenue
Sales tax licensing and resale documentation.
Wyoming sourcing questions
- Does Wyoming have a stem cell law?
- Yes. The Stem Cell Freedom Act, SF 48 of 2026, codified at Wyo. Stat. 35-4-1101 through 35-4-1106 and effective 1 July 2026, lets a patient receive and a registered physician perform stem cell therapy that is not FDA approved, provided the therapy uses the patient’s own mesenchymal stem cells under IRB oversight or investigational product status, cGMP handling, and written informed consent. The Board of Medicine keeps a public registry of registered physicians and may not discipline a registered physician solely for providing compliant therapy.
- Does the Stem Cell Freedom Act cover exosomes?
- No. The Act defines stem cell therapy as treatment involving the use of autologous mesenchymal stem cells, the patient’s own. An exosome preparation derived from donor perinatal tissue falls outside that definition twice over: exosomes are acellular extracellular vesicles rather than stem cells, and a donor-derived product is not autologous. Exosome products in Wyoming are governed by federal law, and no exosome product is FDA approved for administration to humans.
- Who may perform stem cell therapy under the Wyoming Act?
- A physician licensed by the Wyoming Board of Medicine who has registered with the Board to provide therapy under the Act; the Act expressly excludes physician assistants from its definition of physician. The therapy is administered by a physician or under direct physician supervision, within a physician-patient relationship, after written informed consent that acknowledges the therapy is not FDA approved.
- Can a nurse practitioner run a practice in Wyoming without a physician?
- Yes, within APRN scope. Wyoming nurse practitioners hold full practice authority, and the Wyoming State Board of Nursing states that supervision or collaboration agreements with any other provider are not required by Wyoming law. An NP-led practice evaluates, diagnoses, and prescribes within its own scope. Stem cell therapy under the Stem Cell Freedom Act is a separate matter: that Act is physician-only.
- Does my Wyoming clinic need a wholesale distributor license to buy exosomes?
- No. The wholesale distributor license under Wyo. Stat. 33-24-153 is held by the entity distributing prescription drugs into Wyoming, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Does Wyoming enforce the corporate practice of medicine?
- Wyoming does not codify the prohibition the way Texas, New York, or Oregon do, and professional entities alongside management services arrangements are the usual structures. Because the position is not a bright-line statutory rule, published summaries disagree, so treat ownership structure as a question for Wyoming counsel and the Board of Medicine.
- How long does cold-chain shipping take to Wyoming?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Wyoming SF 48 (2026), Stem Cell Freedom Act, enrolled act (accessed 16 October 2026)
- Wyoming State Board of Pharmacy, wholesale distributor licensing (accessed 16 October 2026)
- Wyoming State Board of Nursing, practice information (accessed 16 October 2026)
- Wyoming Board of Medicine (accessed 16 October 2026)
- Wyoming Department of Revenue (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark characterization standard for extracellular vesicles, the scientific basis for this page’s distinction between acellular vesicles and the autologous cells Wyoming’s Act defines.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current revision of the MISEV standard, supporting this page’s point that EV characterization expectations come from the field’s consensus guidelines rather than from any Wyoming statute.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.